These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29243219)

  • 1. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
    Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
    Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
    Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
    Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
    Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
    Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
    Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.
    Zhu YT; Zhao Z; Fu XY; Luo Y; Lei CY; Chen W; Li F; Pang SY; Chen SS; Tan WL
    Stem Cell Res; 2014 Jul; 13(1):111-22. PubMed ID: 24874290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
    Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
    Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
    Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
    J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
    Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
    Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
    Miyake M; Hori S; Ohnishi S; Toritsuka M; Fujii T; Shimizu T; Owari T; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Anai S; Torimoto K; Tanaka N; Fujimoto K
    Cancer Sci; 2019 Oct; 110(10):3315-3327. PubMed ID: 31385407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
    Karyampudi L; Lamichhane P; Scheid AD; Kalli KR; Shreeder B; Krempski JW; Behrens MD; Knutson KL
    Cancer Res; 2014 Jun; 74(11):2974-85. PubMed ID: 24728077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
    Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
    Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
    Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
    Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.